
Can Ozempic Affect Your Eyes or Vision?
Initially approved by the U.S. Food and Drug Administration (FDA) to help control blood sugar and treat type 2 diabetes, semaglutide (brand names Ozempic, Wegovy and Rybelsus) has also emerged as a
read more
Texas Retina Associates Participating in Phase III Clinical Trial for Choroidal Melanoma
Under the leadership of principal investigator Timothy Fuller, MD, Texas Retina is participating in the Phase III AU-011 clinical trial (CoMpass) for treatment of small choroidal (ocular) melanoma. Together with Aura Biosciences,
read more
May is Ocular Melanoma Awareness Month
Ocular (uveal) melanoma is a rare but dangerous disease, and only a small number of doctors in the United States treat it. At Texas Retina, we have been caring for ocular melanoma
read more
Dr. Abbey Shares 36-Month Results of Pegcetacoplan Treatment for Geographic Atrophy in AMD
On behalf of the investigators for the OAKS, DERBY, and GALE clinical trials, Texas Retina’s Director of Clinical Research for Dallas, Ashkan Abbey, MD, co-authored an article titled, “Pegcetacoplan Treatment for Geographic
read more
Dr. Nikisha Kothari Leads Eyetube Interview on a Challenging Surgical Case
Texas Retina’s Nikisha Kothari, MD, recently interviewed one of the 2025 Vit-Buckle Society Meeting presenters about a challenging case for Eyetube. She talked with Andrew Tsai, MD, an adult and pediatric retinal
read more
Dr. Laura Discussed Dry AMD Treatment at 2025 Vit-Buckle Society Annual Meeting
Texas Retina’s Diana M. Laura, MD, participated in a debate at the 13th Annual Vit-Buckle Society Meetingheld recently in Austin, Texas, where she discussed the role of complement inhibitors for the treatment
read more
Dr. Kothari Speaks About Rare Retinal Conditions at 2025 VitBuckle Society Annual Meeting
Texas Retina’s Nikisha Kothari, MD, served on a medical retina panel that reviewed rare retinal conditions, ranging from medication related toxicity and genetic disorders to infectious diseases, at the 13th Annual Vit-Buckle
read more
Texas Retina Clinical Research Coordinator Rachel McCullough Participates in Panel Discussion for LUGANO and LUCIA Clinical Trials
At a recent meeting in San Antonio, Texas Retina Clinical Research Coordinator Rachel McCullough participated in a panel discussion with study coordinators for EyePoint Pharmaceuticals’ pivotal Phase III LUGANO and LUCIA clinical
read more